Riskpilot← Back to searchSign inGet full accessCARDIOPHARMA ApS
APSActiveCVR 13966273Bregnevej 39Business and other management consultancy activities · NACE 7020Est. 1990— employees
Revenue 2025
DKK 0
EBITDA margin
—
+3% vs 2024
Equity ratio
99.9%
Financial strength
Net profit 2025
DKK 2M
-32% vs 2024
| Revenue | DKK 0 | — |
| EBITDA | DKK 2,6M | +3% |
| Net profit | DKK 2M | -32% |
| Total assets | DKK 28,5M | +1% |
| Equity | DKK 28,5M | +1% |
| Employees | — | — |
Legal name
CARDIOPHARMA ApS
CVR number
13966273
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
9. januar 1990
Share capital
DKK 125.000
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2025-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren.
Company purpose
Selskabets formål er handel samt investering, herunder investering i erhvervsdrivende selskaber samt hermed beslægtet virksomhed.
Address
Bregnevej 39
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 50 | 0 | 1.018 | 4.457 | 947 | 35 | 1.758 | 2.397 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -82 | -52 | -108 | 934 | 4.376 | 850 | -68 | 1.661 | 2.097 | 704 | 3.185 | 348 | 2.556 | 2.631 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -82 | -52 | -108 | 934 | 4.376 | 850 | -68 | 1.661 | 2.097 | 704 | 3.185 | 348 | 2.556 | 2.631 |
| Net financials | 428 | 2.603 | 3.144 | 3.183 | 2.318 | 2.561 | 1.243 | 1.850 | 1.878 | 4.387 | 3.155 | 1.112 | 2.973 | 1.989 |
| Profit before tax | 345 | 2.551 | 3.036 | 3.099 | 2.238 | 2.464 | 1.139 | 1.754 | 1.578 | 4.280 | 2.903 | 1.022 | 2.911 | 1.968 |
| Tax | 10 | 38 | -2 | 189 | 23 | -0 | 5 | 25 | 4 | 1 | 2 | 4 | 0 | -0 |
| Net profit | 336 | 2.513 | 3.037 | 2.910 | 2.214 | 2.464 | 1.134 | 1.729 | 1.575 | 4.279 | 2.901 | 1.019 | 2.910 | 1.968 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 13.550 | 15.966 | 18.925 | 21.811 | 22.749 | 24.314 | 24.342 | 25.071 | 26.248 | 30.125 | 28.073 | 28.122 | 28.303 | 28.533 |
| Equity | 13.421 | 15.837 | 18.777 | 20.187 | 21.401 | 23.164 | 24.299 | 25.027 | 26.202 | 30.081 | 27.981 | 28.000 | 28.260 | 28.504 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 129 | 129 | 149 | 1.624 | 1.349 | 1.150 | 43 | 44 | 46 | 44 | 92 | 122 | 43 | 30 |
| Total debt | 129 | 129 | 149 | 1.624 | 1.349 | 1.150 | 43 | 44 | 46 | 44 | 92 | 122 | 43 | 30 |
EBITDA margin
263065900.0%
This company
15.8%
Market median
+1664973951% vs market
20122025
Equity ratio
99.9%
This company
38.2%
Market median
+162% vs market
20122025
Return on equity
6.9%
This company
18.4%
Market median
-63% vs market
20122025
Net profit margin
196838800.0%
This company
8.1%
Market median
+2430108542% vs market
20122025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via CVR / Virk · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via CVR / Virk · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via CVR / Virk · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via CVR / Virk · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via CVR / Virk · Period 2015-05-01 – 2016-04-30
- Annual report 2015Filed via CVR / Virk · Period 2014-05-01 – 2015-04-30
- Annual report 2014Filed via CVR / Virk · Period 2013-05-01 – 2014-04-30
- Annual report 2013Filed via CVR / Virk · Period 2012-05-01 – 2013-04-30
- Annual report 2012Filed via CVR / Virk · Period 2011-05-01 – 2012-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ES Audit | Audit | 1990 | — | — |
FE Audit | Audit | 1992 | — | — |
HS Management | Management | 1990 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 1990 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CARDIOPHARMA ApS 
iAngels Invest Holding 1 A/SBoard members of CARDIOPHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Schwartz | Audit | 0 companies |
| Finn Ellgaard | Audit | 0 companies |
| Henrik Stenbjerre | Management | 0 companies |